Treatment of eosinophlic esophagitis with swallowed topical corticosteroids  

作　　者：Simon Nennstiel Christoph Schlag 

机构地区：[1]Klinikum rechts der Isar der Technischen Universität München,Klinik und Poliklinik für Innere Medizin II,Munich 81675,Germany

出　　处：《World Journal of Gastroenterology》2020年第36期5395-5407,共13页世界胃肠病学杂志（英文版）

摘　　要：Eosinophilic esophagitis(EoE)is an emerging chronic local immune-mediated disease of the esophagus.Beside proton pump inhibitors and food-restrictiondiets swallowed topical corticosteroids(STC)can be offered as a first line therapy according to current guidelines.This review describes the background and practical management of STCs in EoE.So far,mainly asthma inhalers containing either budesonide or fluticasone have been administered to the esophagus by swallowing these medications“off label”.Recently esophagus-targeted formulations of topical steroids have been developed showing clinicopathological response rates up to 85%-an orodispersible tablet of budesonide has been approved as the first“in label”medication for EoE in Europe in June 2018.Whereas it was shown that disease remission induction of EoE by STCs is highly effective,there is still a lack of data regarding long-term and maintenance therapy.However,current studies on STC maintenance therapy add some movement into the game.

关 键 词：Eosinophilic esophagitis Swallowed topical corticosteroids Esophagustargeted formulations of topical steroids FLUTICASONE BUDESONIDE Budesonide orodispersible tablet Budesonide oral suspension 

分 类 号：R571[医药卫生—消化系统]